Aripiprazole

阿立哌唑

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameAripiprazole
Drug Alias NameAripiprazol阿利哌唑阿立派唑AripiprazolumAbilify MyCite +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor agonistsDopamine D4 receptor antagonists +[9] 
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor +[9] 
Therapy Area/IndicationsBipolar I DisorderStress Disorders, Post-TraumaticSchizophrenia +[35] 
Global Approved IndicationsSchizophreniaAutistic DisorderDepressive Disorder, Major +[6] 
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2002/11/15
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOtsuka Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoGenuine Research Center, EgyptUniversity of Texas Southwestern Medical Center +[8] 
Inactive CompaniesFederal University Of Sao PauloGlaxosmithkline PlcSuny Upstate Medical University +[23] 
Active IndicationsSchizophreniaAutistic DisorderAutism Spectrum Disorder +[12] 
Inactive IndicationsBipolar I DisorderStress Disorders, Post-TraumaticPsychotic Disorders +[23] 

Other Information

ATC CodeN05AX12
Related LinksWikipediaDrugBankKEGG